Although Merck spokesman Ron Rogers confirmed that a Fosamax-related deal has been signed, he did not divulge details about the deal, maintaining that the details were proprietary.
Fosamax’s key US patent is set to expire on February 6, 2008, which will clear the way for generic competition. Teva Pharmaceutical Industries and Barr Pharmaceuticals are also expected to launch generic copies of Fosamax.